50 results about "Traumatic brain damage" patented technology

Disclosed are methods of treating traumatic brain injury in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention provides a response liposome for treating traumatic brain injury by targeting a blood-brain barrier loaded drug and a preparation method of the response liposome, and belongs to the field of traumatic brain injury treatment.The response liposome is prepared by preparing TfR-T12 target peptide firstly, then preparing nano-particles with hydrophobic molecular drugs wrapped inside, and finally preparing the TfR-T12 target peptide with the hydrophobic molecular drugs wrapped inside. And finally, preparing the response liposome for treating traumatic brain injury by the targeted blood-brain barrier loaded medicine. According to the application, the TfR-T12 target peptide which is highly expressed in cerebral cortex microvessels and can help a nano-drug to pass through a blood brain barrier through endocytosis is prepared as a target spot, meanwhile, the liposome is subjected to polypeptide modification, and the self-assembly driving force of the nano-particles is improved through process control; the outer surface of the response lipidosome is a target peptide, and the response lipidosome is internally coated with a nano-drug; the liposome can repair the blood brain barrier after injury, improve the blood flow of the brain, improve the drainage of the colloidal lymphatic system, improve the motor and cognitive functions of mice after injury, and reduce the dosage of drugs and various possible side effects caused by the drug dosage.

The present inventive concept provides methods of determining whether a subject has cortical or cerebral visual impairment (CVI) as well as determining whether the subject has a traumatic brain injury thereby allowing treatment for these conditions. The present inventive concept also provides a standardized method for assessing pediatric or adolescent visual acuity.

The disclosure relates to compositions including STING inhibitors. Methods of treating subjects with a traumatic brain injury by administering STING inhibitors are also included.

The utility model relates to the technical field of head-mounted physiotherapy devices, and provides a portable transcranial light supply device for traumatic brain injury rehabilitation. A portable transcranial light supply device used for traumatic brain injury rehabilitation comprises a body, a light source, a light source, a light source, a light source, a light source and a light source, and is characterized in that the body is provided with a front arm and a rear arm; the two ends of the front arm are connected with one end of the first front telescopic arm and one end of the second front telescopic arm respectively. The two ends of the rear arm are connected with one end of the first rear telescopic arm and one end of the second rear telescopic arm respectively. The other end of the first front telescopic arm and the other end of the first rear telescopic arm are connected with a first clamping arm of the clamping part, and the other end of the second front telescopic arm and the other end of the second rear telescopic arm are connected with a second clamping arm of the clamping part. The device has the advantages that the two sides of the two telescopic arms connected with the front arm of the device extend to form the two side light supply modules with the adjustable positions, and the two light supply modules are used for supplying light to the positions close to the temples and correspond to the temporal lobe area of the brain of the human body, and auxiliary treatment can be conducted on the temporal lobe area.

The invention relates to medicine, and more particularly to experimental pharmacology, and can be used for creating pharmaceutical compositions and dosage forms for the treatment of traumatic brain injury. For the purpose of broadening the existing range of drugs for the treatment of traumatic brain injury, the use of human apolipoprotein A-I or functionally significant fragments thereof is proposed, wherein the claimed drug contains native apolipoprotein A-I obtained from human blood serum, or recombinant human apolipoprotein A-I, or a functionally significant fragment of human apoA-I. The functionally significant fragment of human apoA-I has a sequence consisting of the amino acid sequence of human apoA-I truncated at the N terminal, and more particularly the amino acid sequence of human apoA-I truncated at the N terminal by 2 amino residues (amino acid residues 3-243). The drug is provided in the form of a pharmaceutical composition containing human apolipoprotein A-I or the functionally significant fragment thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is water for injection or saline solution. A method for treating traumatic brain injury includes locally or parenterally administering said drug to a subject in need thereof in therapeutically effective doses.

Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.

Disclosed herein are methods to aid in determining whether a subject has a traumatic brain injury (TBI) by detecting the level of at least one biomarker, glial fibrillary acidic protein (GFAP), in a sample taken from a subject, such as a human subject, who has undergone a head CT scan that is negative for TBI.

Provided are systems, methods, and devices for providing mediation of a traumatic brain injury. Systems may include an interface, processing devices, and a controller. The interface is configured to obtain measurements from a brain of a user with a traumatic brain injury. A first processing device is configured to generate multiple brain state parameters characterizing one or more features of a brain state of the user. A second processing device is configured to generate models of the brain of the user based on the plurality of brain state parameters and the plurality of measurements, and determine, using the models and training data comprising one or more mediation data points, a mediation procedure for reducing one or more symptoms of the traumatic brain injury. The mediation procedure is provided to one or more entities, and one or more control signals are generated by the controller based on the mediation procedure.

The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).

The application discloses a carrier for engineering miR-124-3p The application discloses an application of an exosome hydrogel in preparation of a drug for treating traumatic brain injury, and belongs to the technical field of biological carrier drug delivery. miR-124- 3p The exosome vesicle structure can improve the stability of the miRNA in the body and the delivery efficiency of the miRNA into nerve cells, thereby enhancing the bioavailability. The engineering exosome is embedded in the QCC / OHM hydrogel system, so that the engineering exosome forms a stable delivery platform at the injury site, realizes sustained release and local enrichment of the exosome. The hydrogel material has good tissue adaptability, can enter irregular brain injury interstitial spaces through minimally invasive injection and form a scaffold structure, and provides a favorable microenvironment for nerve repair. The application can overcome the problems of poor stability of treatment molecules, short local retention time and difficulty in realizing multi-mechanism synergistic treatment, and provides a new technical scheme for treatment of traumatic brain injury.

A method, a structure, and a computer system for traumatic event detection. The exemplary embodiments may include collecting data using sensors worn by a user and identifying a traumatic event based on applying a model to the data, wherein the model correlates values of the data with traumatic events and traumatic brain injuries. The exemplary embodiments may further include identifying the traumatic brain injury resulting from the traumatic event.

The invention relates to the technical field of biological medicine and polymer targeted delivery, and provides an oligodendrocyte-derived exosome and application thereof in preparation of a medicine for treating traumatic brain injury. Comprising the following steps: separating and culturing primary oligodendroglia cells from brain tissues; placing the maturely cultured oligodendroglia cells in a sugar-free and serum-free culture medium, performing oxygen-glucose deprivation treatment in an anoxic environment, then continuously culturing in a normal sugar-containing culture medium under a normal oxygen condition, and collecting cell culture supernate; and separating the exosome of the oligodendroglia cells subjected to oxygen-glucose deprivation treatment from the supernate by adopting a gradient ultracentrifugation method to obtain the exosome of the oligodendroglia cells subjected to oxygen-glucose deprivation treatment. The exosome derived from the oligodendroglia is applied to preparation of the medicine for treating the traumatic brain injury and has the advantages of being high in targeting performance and good in penetrability, that is, the exosome is used as a natural carrier, the defect that a traditional traumatic brain injury medicine is difficult to penetrate through a blood brain barrier is perfectly overcome, and the exosome can efficiently enter brain tissue and be taken by microglia.

The present disclosure relates generally to compositions and methods for determining whether a patient has traumatic brain injury (TBI) by detecting the presence of amyloid beta protein in the eye of the patient. Compositions and methods for preparing a patient to diagnose and treat traumatic brain injury (TBI) are also provided.

Here disclosed is a set of biomarkers useful for diagnosis, prognosis, treatment, determining the short- and long-term effects of traumatic brain injury (TBI) in a subject. Methods for using the biomarkers also are described.

The invention relates to the technical field of medical preparations, in particular to application of a polyethylene glycol bovine hemoglobin conjugate. By constructing a traumatic brain injury rat model, it is found that the polyethylene glycol bovine hemoglobin conjugate can effectively improve learning cognition, memory and exercise capabilities, new application of the polyethylene glycol bovine hemoglobin conjugate is expanded, a new thought is provided for research and development of drugs for improving the learning cognition, memory and exercise capabilities, and the application of the polyethylene glycol bovine hemoglobin conjugate is developed. Wide application prospects are realized.

The present disclosure generally relates to compositions and methods for determining whether a patient has suffered a traumatic brain injury (TBI) by detecting the presence of amyloid beta protein in the patient's eyes. Compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TBI) are also provided.

To provide 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids, and methods for use thereof.SOLUTION: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.SELECTED DRAWING: None

The invention relates to a combination of biomarkers and their use in brain injury or mild traumatic brain injury (mTBI) detection. The invention also relates to methods of treating the individual diagnosed with a traumatic brain injury (TBI) or a mild traumatic brain injury (mTBI) using such biomarkers.

The invention relates to a traumatic brain injury subtype real-time grading method which comprises the following steps: introducing a space-time injury evolution unit TEU as a basic structure unit, and fusing an injury part, an influence range and a change trend; extracting a brain tissue density change rate and a hemorrhage boundary form change parameter through imaging data; generating a dynamic damage characteristic data body which is jointly expressed by a time sequence chain and a structural atlas; extracting a change function curve of the damaged unit; establishing a variation mode feature pool; different subtypes are distinguished under similar image expression through a nonlinear change mode; generating a group of risk potential functions RPF for the damage subtype, and calculating a structure damage rate, spatial diffusion tension and key brain region proximity; constructing a risk change acceleration function by using the derivative of the RPF, and triggering level self-adjustment when the risk value change speed exceeds a critical point; constructing a grading state credibility label, and distinguishing a high credibility grade and a boundary grade; and in combination with a clinical rule base and a dynamic grading result, structured suggestions are generated, and the clinical reaction efficiency is improved.

The present invention provides compounds, compositions and methods for prophylaxis and treatment of traumatic brain injury using a P13 peptide or P13 fusion peptide which can be administered prior to or after traumatic brain injury and which can ameliorate the biophysiological indicators of brain injury and improve neurological outcomes in subjects suffering from traumatic brain injury.

The invention discloses a traumatic brain injury patient intracranial pressure continuous prediction method based on an LSTM model, and belongs to the technical field of medical monitoring. Comprising the steps that intracranial pressure data of a patient are collected in real time through an invasive intracranial pressure monitor, and the sampling rate is 100 Hz; the collected data are preprocessed, the reasonable range is set to be-5 mmHg to 50 mmHg, sliding window smoothing processing and abnormal value detection are adopted, and normalization processing is carried out; training an LSTM (Long Short Term Memory) model by using the preprocessed data, wherein an initial training set is data of each patient in the first 30 minutes; the trained LSTM model is used for outputting an intracranial pressure predicted value in the next 10 minutes every 10 minutes; high and low intracranial pressure events are classified on the basis of the predicted values, and when no less than 6 predicted values in the 10 predicted values exceed 20 mmHg, the high intracranial pressure events are judged; and updating the LSTM model according to newly acquired data to realize adaptive optimization. The method is suitable for real-time monitoring of traumatic brain injury patients, provides the dynamic trend of the intracranial pressure through continuous prediction, and provides support for clinical decision making.

Embodiments of the present disclosure relate to methods of using bupivacaine multivesicular liposomes for stellate ganglion block to treat or ameliorate anxiety disorders or traumatic brain injury associated with the over-active or unbalanced sympathetic nervous system, including but not limited to versatile anxiety disorders, panic disorders, and post-traumatic stress disorders.

BAG3 proteins are used in the treatment of, for example, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Lewy body disease, vascular dementia, mixed dementia, and traumatic brain injury, for example, complicated by chronic traumatic encephalopathy (CTE). Therapeutically effective BAG3 compositions, uses of BAG3, and methods of treating BAG3 are described.

Methods and devices related to blast and environmental exposure monitoring, introducing a risk-based model for system deployment, and at its highest level, performing head-based blast vectoring within the system for monitoring the exposure and post-event surveillance, including biometric data acquisition, and probing behavioral indicators to perform device driven traumatic brain injury risk assessment.

A system to rehabilitate stroke or traumatic brain injury survivors includes a brain machine interface that receives brain signals from the brain of a patient. The brain signals represent motor intent of the patient with respect to a hand of the patient that has impaired dexterous hand function due to neurological injury. A limb interface mounts to the hand of the patient. The limb interface detects feedback in the hand that results from the brain signals and helps to control the hand in accordance with the motor intent of the brain signals. The system also includes a processor operatively coupled to the brain machine interface and the limb interface. The processor is configured to synchronize the motor intent with the feedback to increase plasticity between sensory and motor areas of the brain to improve voluntary control of the hand, including dexterous hand functions such as multiple types of grasp.

A method for treating traumatic brain injury include administering to a patient having traumatic brain injury and in need of treatment an effective amount of a composition comprising resveratrol triacetate or esterified resveratrol. The traumatic brain injury may be a penetrating brain injury.

Method and systems for translating biological signals to perform various operations associated with a computing device is provided. The method can include accessing biological-signal data that was collected by a biological-signal data acquisition assembly that comprises a housing having one or more clusters of electrodes. Each cluster of the one or more clusters of electrodes can include at least an active electrode. The method can also include identifying, based on the biological-signal data, a first signal that represents a first intent to move a first portion of a body of the subject. The first signal is generated before a second signal, in which the second signal represents a second intent to move a second portion of the body of the subject. The method can also include translating the first signal to identify a first operation to be performed by a computing device.

The present invention provides elastic assemblies used to model tissues or organs of interest. In one embodiment, detailed herein, the assemblies are designed to model the blood brain barrier following a traumatic brain injury. The present invention also provides elastic membranes on which the assemblies are built, kits from which the assemblies may be prepared, and systems that expand upon the assemblies, forming more physiologically relevant models. Methods for making and using the disclosed devices are also provided.

The present disclosure provides a composition comprising an active ingredient that is encapsulated in suspension of particles comprising a biodegradable polymer containing an effective amount of the active ingredient, wherein the particles are configured to bypass the blood brain barrier, wherein the nutraceutical agent is synthetic D-beta hydroxybutyrate, and wherein targeted delivery is to the brain. It further provides a method for promoting healing of the brain after a traumatic brain injury comprising neuroinflammation and a method for promoting brain health. It further provides a pharmaceutical composition for use in reducing risk of brain damage due to an acquired brain injury in a subject susceptible to, or otherwise at risk of, the acquired brain injury, said composition comprising a pharmaceutically acceptable carrier and a formulation comprising a therapeutic amount of an API, wherein the API is a synthetic D-beta-hydroxybutyrate, wherein the treatment comprises targeted delivery to the olfactory region of the nasal cavity of the subject by administering the composition intranasally (a) before the subject participates in an event where an acquired brain injury is a known risk; (b) after the subject participates in the event for use in treating symptoms of the acquired brain injury of the subject comprising neuroinflammation; or both, wherein the treatment is neuroprotective.